Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
- 1 March 2011
- journal article
- Published by Future Medicine Ltd in Pharmacogenomics
- Vol. 12 (3), 411-421
- https://doi.org/10.2217/pgs.10.187
Abstract
Aim: A cost–effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. Materials & methods: A decision model was developed, and model inputs were taken from the literature and publicly available sources. The perspective of the healthcare sector in the Netherlands was used. Sensitivity and scenario analyses were performed to assess uncertainty in the results. Results: Companion diagnostics could improve health and reduce costs, despite the estimates being uncertain owing to limited evidence for comparative effectiveness between dasatinib and nilotinib. The results were sensitive to the cost of treatment, utility of progression and progression-free survival. Conclusion: This case demonstrates the use of cost–effectiveness analysis at an early stage of health technology assessment to generate economic evidence for the use of companion diagnostics in treatment decisions and to support decision-making for their development.Keywords
This publication has 39 references indexed in Scilit:
- Economic Opportunities and Challenges for PharmacogenomicsAnnual Review of Pharmacology and Toxicology, 2010
- Pharmacogenetics in Europe: Barriers and OpportunitiesPublic Health Genomics, 2009
- Pharmacogenomics, Evidence, and the Role of PayersPublic Health Genomics, 2009
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening ProgrammesPharmacoEconomics, 2008
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- The role of companion diagnostics in the development and use of mutation-targeted cancer therapiesNature Biotechnology, 2006
- ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001